|
Video: What is a Stock Split?
|
|
Biofrontera is a biopharmaceutical company focusing on commercialization of pharmaceutical products. Co.'s principal product is Ameluz®, which is a prescription drug approved for use in combination with its licensor's medical device, which has been approved by the U.S. Food and Drug Administration, the BF-RhodoLED® lamp, for photodynamic therapy, or PDT, (when used together, Ameluz® PDT) in the U.S. for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. Co.'s second prescription drug product in its portfolio is Xepi® (ozenoxacin cream, 1%), a topical non-fluorinated quinolone that inhibits bacterial growth. According to our BFRI split history records, Biofrontera has had 1 split. | |
|
Biofrontera (BFRI) has 1 split in our BFRI split history database. The split for BFRI took place on July 05, 2023. This was a 1 for 20 reverse split, meaning for each 20 shares of BFRI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as Biofrontera conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the BFRI split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Biofrontera shares, starting with a $10,000 purchase of BFRI, presented on a split-history-adjusted basis factoring in the complete BFRI split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/01/2021 |
|
End date: |
05/01/2024 |
|
Start price/share: |
$82.80 |
|
End price/share: |
$1.96 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-97.63% |
|
Average Annual Total Return: |
-77.65% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$236.64 |
|
Years: |
2.50 |
|
|
|
Date |
Ratio |
07/05/2023 | 1 for 20 |
|
|